Teva Releases Q4 2025 Aide Memoire

Rhea-AI Summary

Teva (NYSE: TEVA) posted its Q4 2025 Aide Memoire on the company's Investors page to help investors ahead of fourth-quarter results.

The Aide Memoire compiles previously disclosed public information, prior results, management commentary and select independent data. Q4 2025 results are scheduled for Wednesday, January 28, 2026 at 7:00 AM ET, followed by a conference call at 8:00 AM ET.

News Market Reaction

+1.14%

1 alert

+1.14% News Effect

On the day this news was published, TEVA gained 1.14%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Harel ownership: 58,118,222 shares Shares outstanding: 1,147,150,917 shares Pooled public funds: 56,881,124 shares +5 more

8 metrics

Harel ownership 58,118,222 shares SCHEDULE 13G reporting 5.1% of Teva’s ordinary shares

Shares outstanding 1,147,150,917 shares Ordinary shares outstanding as of June 30, 2025

Pooled public funds 56,881,124 shares Held for pooled public funds per SCHEDULE 13G filing

Insider purchase size 1,113 shares Open-market buy by EVP & CLO on 09/05/2025

Insider purchase price $18.8572 per share Price paid in 09/05/2025 Form 4 transaction

Insider holdings post-buy 13,027 shares Ordinary shares beneficially owned after transaction

Short interest 4.4% of float Reported short position relative to free float

Days to cover 4.7 days Based on current short interest and trading volume

Market Reality Check

Price: $32.14 Vol: Volume 9,271,311 vs 20-da...

normal vol

$32.14 Last Close

Volume Volume 9,271,311 vs 20-day average 10,948,410 (relative volume 0.85x) suggests typical trading ahead of the update. normal

Technical Price $29.79 is trading above the 200-day MA $18.33, reflecting a sustained uptrend into Q4 results.

Peers on Argus

TEVA gained 1.28% while peers were mixed: UTHR +0.61%, VTRS 0%, TAK +0.35%, RDY ...

TEVA gained 1.28% while peers were mixed: UTHR +0.61%, VTRS 0%, TAK +0.35%, RDY -0.5%, NBIX -1.43%. This points to a stock-specific drift rather than a broad sector move.

Historical Context

5 past events · Latest: Dec 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 09	Regulatory filing	Positive	+0.8%	FDA NDA submission for once-monthly olanzapine LAI schizophrenia treatment.
Nov 25	Regulatory approval	Positive	+0.9%	EU marketing authorizations for two denosumab biosimilars supporting biosimilar strategy.
Nov 21	Investor conferences	Neutral	+2.3%	Management participation in three December healthcare investor conferences.
Nov 19	AI initiative launch	Positive	-1.6%	Launch of Teva Rise open innovation platform focused on AI and Industry 4.0.
Nov 07	Clinical data update	Positive	+1.2%	Interim IMPACT-TD real-world AUSTEDO data showing symptom and life-quality gains.

Pattern Detected

Recent fundamentally positive headlines have mostly seen modest positive price reactions, with one AI-focused initiative drawing a negative move.

Recent Company History

Over the past months, Teva reported several milestones. On Nov 7, 2025, real‑world AUSTEDO data showed meaningful patient improvements. On Nov 19, 2025, the company launched the Teva Rise AI and innovation platform. Later in November, it received European Commission approvals for two denosumab biosimilars and scheduled multiple December investor conference appearances. On Dec 9, 2025, Teva submitted an FDA NDA for olanzapine LAI. Today’s Q4 2025 aide-mémoire supports investor preparation ahead of the upcoming earnings release.

Market Pulse Summary

This announcement alerts investors that Teva’s Q4 2025 aide-mémoire is available ahead of results ex...

Analysis

This announcement alerts investors that Teva’s Q4 2025 aide-mémoire is available ahead of results expected on January 28, 2026, with a conference call at 8am ET. The document compiles prior disclosures and outlook commentary, helping frame expectations without adding new fundamentals. In context of recent regulatory wins, clinical updates, and innovation initiatives, investors may focus next on the actual Q4 performance, forward guidance, and any strategic updates during the earnings call.

Key Terms

New Drug Application, long-acting injectable, Phase 3, biosimilars, +4 more

8 terms

New Drug Application regulatory

"submitted a New Drug Application (NDA) to the FDA on December 9, 2025"

A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.

long-acting injectable medical

"an investigational once-monthly subcutaneous long-acting injectable (LAI)"

A long-acting injectable is a medication formulated to be given by shot that releases its active ingredient slowly over weeks or months so a patient needs fewer doses. For investors, these products can change a drug’s market value by improving patient convenience and adherence, extending patent life or pricing opportunities, and requiring different manufacturing and regulatory steps compared with daily pills — much like swapping many small payments for a single, larger subscription.

Phase 3 medical

"The NDA is supported by Phase 3 SOLARIS trial data"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

biosimilars medical

"two denosumab biosimilars: PONLIMSI (biosimilar to Prolia)"

Biosimilars are medicines made to be highly similar to an already approved biological drug produced from living cells, with no meaningful differences in safety or effectiveness. They matter to investors because they introduce lower‑cost competition to expensive biologic treatments—similar to how generic drugs compete with brand drugs—but involve more complex manufacturing, regulatory review and patent risk, which can affect market share, pricing and profit margins across the sector.

marketing authorizations regulatory

"the European Commission granted marketing authorizations on Nov 25, 2025"

A marketing authorization is an official government approval that allows a company to sell a drug, medical device, or health product in a particular country or region. It matters to investors because it is the legal key to generate revenue and reach customers—like a driver’s license for a product—so obtaining, losing, or delaying authorization directly affects a company’s potential sales, regulatory risk and valuation.

Abnormal Involuntary Movement Scale medical

"The Abnormal Involuntary Movement Scale (AIMS) total motor score fell"

AIMS is a standardized clinical checklist doctors use to spot and rate involuntary movements—like facial grimacing, tongue or limb twitching—that can be caused by certain medications. For investors, AIMS scores matter because they are a practical safety measurement in drug trials and ongoing monitoring; high or worsening scores can lead to stronger warnings, tougher regulatory review, reduced marketability or costly label changes, much like a vehicle inspection report revealing serious faults.

SCHEDULE 13G regulatory

"[SCHEDULE 13G] TEVA PHARMACEUTICAL INDUSTRIES LTD SEC Filing"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

Form 4 regulatory

"[Form 4] Teva Pharmaceutical Industries Limited American Insider Trading Activity"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

AI-generated analysis. Not financial advice.

TEL AVIV, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q4 2025 Aide Memoire is available on the “Investors” page on its website.

Q4 2025 Aide Memoire

Teva has compiled this document with public information that was previously provided by Teva in order to assist investors ahead of fourth quarter 2025 results, which are expected to be released on Wednesday, January 28, 2026 at 7am ET, followed by a conference call at 8am ET. The document is based on Teva’s prior results, management’s previous commentary about Teva’s business outlook and data from select independent sources.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com. 

Cautionary Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the third quarter of 2025, and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned "Risk Factors” and “Forward-Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com

Teva Investor Relations Inquiries
TevaIR@Tevapharm.com

FAQ

Where can I find Teva's Q4 2025 Aide Memoire (TEVA)?

The Aide Memoire is available on Teva's Investors page on the company's website.

When will Teva (TEVA) release Q4 2025 results and what time is the conference call?

Teva will release Q4 2025 results on January 28, 2026 at 7:00 AM ET, with a conference call at 8:00 AM ET the same day.

What information does Teva's Q4 2025 Aide Memoire include for investors?

The document compiles Teva's previously provided public information, prior results, management commentary, and select independent data.

Is Teva's Q4 2025 Aide Memoire new guidance or forward-looking guidance (TEVA)?

The Aide Memoire summarizes previously disclosed information and commentary; it does not present new forward-looking guidance.

Will Teva's Q4 2025 conference call include a live webcast for investors?

The announcement lists a conference call at 8:00 AM ET; check Teva's Investors page for webcast or dial-in details.